CVE-2014-3084

Description

IBM Maximo Asset Management 6.1 through 6.5, 7.1 through 7.1.1.13, and 7.5 through 7.5.0.6; Maximo Asset Management 7.5.0 through 7.5.0.3 and 7.5.1 through 7.5.1.2 for SmartCloud Control Desk; and Maximo Asset Management 6.2.8, 7.1, and 7.2 for Tivoli IT Asset Management for IT and certain other products allow remote authenticated users to bypass intended write-access restrictions on calendar entries via unspecified vectors.

Category

4.9
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.55%
Vendor Advisory ibm.com Vendor Advisory ibm.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://www-01.ibm.com/support/docview.wss?uid=swg1IV61274 vendor advisory
http://www.securitytracker.com/id/1030780 vdb entry
http://www-01.ibm.com/support/docview.wss?uid=swg21681020 vendor advisory
http://secunia.com/advisories/60453 third party advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/93955 vdb entry
http://secunia.com/advisories/60408 third party advisory

Frequently Asked Questions

What is the severity of CVE-2014-3084?
CVE-2014-3084 has been scored as a medium severity vulnerability.
How to fix CVE-2014-3084?
To fix CVE-2014-3084, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2014-3084 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2014-3084 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.